AI Article Synopsis
- - The COVID-19 pandemic has evolved over the past three years, leading to significant new findings in epidemiology, transmission, diagnosis, and treatment, particularly for lung transplant recipients.
- - Research has highlighted several key therapeutics for COVID-19, including antivirals like remdesivir and nirmatrelvir/ritonavir, monoclonal antibodies, and immunomodulators such as corticosteroids.
- - Remdesivir is crucial for treating mild to moderate cases, while the use of nirmatrelvir in lung transplant patients is limited due to drug interactions; monoclonal antibodies struggle with varying viral strains.
Article Abstract
Purpose Of Review: The landscape of the coronavirus disease 2019 (COVID-19) pandemic has rapidly changed over the past 3 years. Paralleling this evolution, the scientific and medical communities have reported many novel findings relating to the infection's epidemiology, transmission, diagnosis, and treatment. We review pertinent studies of COVID-19 therapeutics with an emphasis on their application to lung transplant recipients.
Recent Findings: Agents that have been well-studied for treating COVID-19 include antivirals (remdesivir, nirmatrelvir/ritonavir, molnupiravir), monoclonal antibodies, and immunomodulators (for example, corticosteroids and tocilizumab).
Summary: Remdesivir remains an essential therapy for managing mild-moderate COVID-19. Though highly efficacious for mild-moderate COVID-19 for outpatient therapy, ritonavir-boosted nirmatrelvir has limited use in lung transplant recipients due to significant drug-drug interactions. Monoclonal antibodies, though useful, are the most affected by the emergence of new viral variants.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932416 | PMC |
| http://dx.doi.org/10.1007/s13665-023-00302-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!